Development of new skin neoplasms in patients with history of basal cell carcinoma
Keywords:
Basal cell carcinoma, subsequent skin tumors, history of skin cancer, non-melanoma skin cancer, keratinocyte tumorsAbstract
Introduction: The risk of developing a second basal cell carcinoma in years after diagnosis has been a topic of debate. There is insufficient literature from abroad and in the country on the quantification
of the risk of subsequent neoplasms in patients with a personal history of skin cancer.
Objective: To identify the occurrence of new basal cell carcinomas according to previous history in patients with multiple lesions.
Material and Methods: An observational and retrospective
study was carried out. The universe consisted of 2 038 patients with histopathological diagnosis of one or more skin tumors, registered in the
pathological anatomy archive of the hospital Dr. "Mario Muñoz Monroy" of the municipality of Colón, Matanzas, between 2010 and 2019. The sample was 1 178 patients aged 18 years or older, regardless of the number of skin tumors and those who had at least a basal cell carcinoma in their tumor profile. The variables were age, sex, histological diagnosis and year of diagnosis. The SPSS version 20.0 statistical package was used. The information was processed by descriptive statistics.
Results: There were 992 patients with single injury and 186 with
multiple injuries. The total of malignant lesions was 1 484, including 1374 basal cell carcinoma, 97 epidermoid carcinomas, and 13 remaining skin neoplasms. The mean age was 65 years, with male predominance. With respect to the tumor profile of the patient, the BCC prevailed among
subsequent lesions.
Conclusions: The history of basal cell carcinoma in men over 50 years increases the probability of a new carcinoma of this type.
Downloads
References
1. Ministerio de Salud Pública (CUB). Sección Independiente de Control del Cáncer. Prevención, diagnóstico y tratamiento del cáncer de piel [Internet]. La Habana: Editorial Ciencias Médicas, 2023. Disponible en: http://www.bvscuba.sld.cu/libro/prevencion-diagnostico-y-tratamientodel-cancer-de-piel/
2. Nanz L, Keim U, Katalinic A, Meyer T, Garbe C, Leiter U. Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. Cancers [en línea] 2024 [Citado: 2024 mayo 02]; 16:606. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854623/pdf/cancers-16-00606.pdf
3.Ciążyńska M, Lange D, Lewandowski B, Reich A, Sławińska M, Pabianek M, et al. The incidence and clinical analysis of non melanoma skin cancer. Scientific Reports [en línea] 2021. [Citado: 2023 agosto 02]; 11: 4337. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900109/pdf/41598_2021_Article_83502.pdf
4.Venables ZC, Nijsten T, Wong KF, Autier P, Broggio J, Deas A et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013–15: a cohort study. British Journal of Dermatology [en línea] 2019 March. [Citado: 2022 octubre 02];181: 474-82 .Disponible en: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC7379277/pdf/BJD-181-474.pdf
5.Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25years. BMC Cancer [en línea] 2022. [Citado: 2023 agosto 02]; 22: 36. Disponible en: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC9339183/pdf/12885_2022_Article_9940.pdf
6.Ballesteros-Zurita N, Melena-Zapata J, Narváez-Olalla A. Perfil epidemiológico del cáncer de piel en Ecuador. Estudio Observacional Descriptivo. Revista Médica Vozandes [en línea] 2023 Julio. [ Citado: 2024 febrero 02]; 34(1):33-40. Disponible en: http://revistamedicavozandes.com/wp-content/uploads/2023/07/05_AO3-1.pdf
7.Miolo N, Rodrigues RF, da Silva ER, Piati PK, Campagnolo OA, Marques LF. Skin cancer incidence in rural workers at a reference hospital in western Paraná. An Bras Dermatol [en línea] 2019 Mar-April. [Citado: 2022 octubre 02]; 94 (2): [7 p.p]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486073/
8.Matthews NH, Fitch K, Li WQ, Morris JS, Christiani DC, Qureshi AA et al. Exposure to trace elements and risk of skin cancer: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev [en línea] 2019 January. [Citado: 2022 octubre 02]; 28 (1): [43 p.p]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324965/
9.Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Córdoba M et al. Basal cell carcinoma. Contemporary approaches to diagnosis, treatment, and prevention. J Am Acad Dermatol [Internet]. 2019 February. [Citado: 2022 octubre 02];80(2):303-17. Disponible en: https://www.jaad.org/article/S0190-9622(18)30776-X/fulltext
10.Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud. La Habana; 2022. Disponible en:
http://salud.msp.gob.cu/wp-content/Anuario/Anuario-2022.pdf
11.Ruiz-González JF, Guevara-Gutiérrez E, Hernández-Torres M, Solís-Ledesma GS, Tlacuilo-Parra A. Riesgo de recurrencia y de nuevas neoplasias cutáneas malignas en .sujetos mexicanos con carcinoma basocelular. Cirugía y Cirujanos [en línea] 2018. [Citado: 2022 octubre 02];86 (5):417-22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30226497/
12. Duarte AF, Sousa-Pinto B, Haneke E, Correia O. Risk factors for development of new skin neoplasm in patients with history of skin cancer: A survival analysis. Scientific reports 2018; 8:15744. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200724/
13. McLoone NM, Tolland J, Walsh M, Dolan OM. Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol. [en línea] 2006. [Citado: 2022 octubre 02]; 20:698-701. Disponible en: http://pubmed.ncbi.nlm.nih.gov/16836498/
14.Giuglea C, Marin A, Gavrila I, Paunescu A, Dobrete AA, Marinescu SA. Basal Cell Carcinoma—A Retrospective Descriptive Study Integrated in Current Literature. Life [Internet] 2023. [Citado: 2023 mayo 20];13: 832 Disponible en: https://doi.org/10.3390/life13030832
15. Sánchez V, Carpio E, Fardales VE, Martínez B, Arias AI, Brito E et al. Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon. Anais Brasileiros de Dermatología. [en línea] 2023. [Citado 23 Feb 2024]; Disponible ehttp://clinics.elsevier.es/pt-long-term-follow-up-patients-with-high-risk-avance-S0365059624000217
16. Flohil SC, Koljenović S, de Haas RM, Overbeek LI, de Vries E, Nijsten T. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands.Br J Dermatol [en línea] 2011 October.[Citado: 2022 octubre 02]; 165(4):874-81. Disponible en: http://pubmed.ncbi.nlm.nih.gov/21711333/
17. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol [en línea] 2000. [Citado: 2022 octubre 02];136 (12): 1524-30. Disponible en: http://jamanetwork.com/journals/jamadermatology/fullarticle/190904
18. Karagas MR, Stukel TA, Greenberg RE, Baron JA, Mott LA, Stern RS. Risk of Subsequent Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Among Patients with Prior Skin Cancer. J Am Acad Dermat [en línea] 1992. [Citado: 2022 octubre 02];267(24):3305-3310. Disponible en: http://jamanetwork.com/journals/jama/article-abstract/398060
19.Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol [en línea] 1993.January. [Citado: 2022 octubre 02];28 (1): 22-8. Disponible en: http://www.pubmed.ncbi.nlm.nih.gov/8425966/
20. Schreuder K, Hollestein L, Nijsten TEC, Wakkee, Louwman MWJ. A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence. British Journal of Dermatology [en línea] 2022 October. [Citado: 2023 abril 12]; 186:476-84. Disponible en: http://click.endnote.com/viewer?doi=10.1111/bjd.20871&route=2
http://pubmed.ncbi.nlm.nih.gov/34726263/
21.Turner LD, Zarkovic A, Siew JL, Chan W, Ogra S, Brettekk D, Ohana O et al. Does the histopathological subtype of primary basal cell carcinoma predict the subtype of secondary tumours? What role do genetic mutations play? Skin Health Dis [en línea] 2023. [Citado: 2024 mayo 02];3(2):e123. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066757/pdf/SKI2-3-e123.pdf
22. Flohil SC, van der Leest RJT, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer [en línea] 2013. [Citado: 2022 octubre 02];49(10): 2365–75. Disponible en: http://www.onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.12887
23.Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC. Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermat [en línea] 2009. [Citado: 2022 octubre 02]; 61(2):247–51. Disponible en: http://www.jaad.org/article/S0190-9622(09)00355-7/fulltext
24. Kyrgidis A, Vahtsevanos K, Tzellos TG, Xirou P, Kitikidou K,Antoniades K et al.
Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient‐cohort study from a tertiary cancer referral hospital. Eur J Dermatol. 2010;20(3):276–82. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20406722/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Habanera de Ciencias Médicas
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the content of this magazine is in Open Access, distributed according to the terms of the Creative Commons Attribution-Noncommercial 4.0 License that allows non-commercial use, distribution and reproduction without restrictions in any medium, provided that the primary source is duly cited.
Download PDF
